Cover Image
市場調查報告書

重金屬中毒症治療藥:開發中產品分析

Heavy Metal Poisoning - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 484621
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
重金屬中毒症治療藥:開發中產品分析 Heavy Metal Poisoning - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 40 Pages
簡介

本報告提供重金屬中毒症治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中治療藥,治療藥評估,暫停中·中止的計劃等相關資訊。

簡介

  • 調查範圍

重金屬中毒症 - 概要

重金屬中毒症 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

重金屬中毒症 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

重金屬中毒症的開發治療藥的企業

重金屬中毒症 - 藥物簡介

重金屬中毒症 - 暫停中的計劃

重金屬中毒症 - 開發中止的產品

重金屬中毒症 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9773IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heavy Metal Poisoning - Pipeline Review, H2 2017, provides an overview of the Heavy Metal Poisoning (Toxicology) pipeline landscape.

Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdominal cramps, tinnitus, goiter, anorexia and diarrhea. Treatment includes chelation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heavy Metal Poisoning - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 5 respectively. Similarly, the Universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Heavy Metal Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Heavy Metal Poisoning (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Heavy Metal Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Heavy Metal Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Heavy Metal Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Heavy Metal Poisoning (Toxicology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Heavy Metal Poisoning (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Heavy Metal Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Heavy Metal Poisoning - Overview
    • Heavy Metal Poisoning - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Heavy Metal Poisoning - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Heavy Metal Poisoning - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals Inc
    • La Jolla Pharmaceutical Company
    • Medesis Pharma SA
    • PDX Pharmaceuticals LLC
  • Heavy Metal Poisoning - Drug Profiles
    • ALN-TMP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • deferasirox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • deferoxamine mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emeramide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hinokitiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJPC-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NU-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NU-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDX-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Heavy Metal Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Zn-DTPA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Heavy Metal Poisoning - Dormant Projects
  • Heavy Metal Poisoning - Discontinued Products
  • Heavy Metal Poisoning - Product Development Milestones
    • Featured News & Press Releases
      • Mar 30, 2017: SRI International Receives U.S. FDA Clearance for Investigational New Drug Application Evaluating Novel Oral Treatment to Combat Radiation Exposure
      • Sep 11, 2015: La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Heavy Metal Poisoning, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Heavy Metal Poisoning - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
  • Heavy Metal Poisoning - Pipeline by La Jolla Pharmaceutical Company, H2 2017
  • Heavy Metal Poisoning - Pipeline by Medesis Pharma SA, H2 2017
  • Heavy Metal Poisoning - Pipeline by PDX Pharmaceuticals LLC, H2 2017
  • Heavy Metal Poisoning - Dormant Projects, H2 2017
  • Heavy Metal Poisoning - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Heavy Metal Poisoning, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top